Q2 EPS Forecast for Akebia Therapeutics Lowered by Analyst

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for Akebia Therapeutics in a research note issued on Friday, February 6th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.05 EPS, FY2026 earnings at $0.12 EPS, FY2029 earnings at $0.30 EPS and FY2030 earnings at $0.44 EPS.

A number of other research analysts also recently commented on the stock. Piper Sandler dropped their price objective on shares of Akebia Therapeutics from $6.00 to $4.00 and set an “overweight” rating for the company in a research note on Friday. Wall Street Zen downgraded Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. BTIG Research reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Akebia Therapeutics in a research report on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Akebia Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.60.

Akebia Therapeutics Trading Up 0.7%

NASDAQ AKBA opened at $1.39 on Monday. The stock has a market capitalization of $368.86 million, a PE ratio of -19.85 and a beta of 0.38. The company has a quick ratio of 1.80, a current ratio of 1.94 and a debt-to-equity ratio of 1.15. Akebia Therapeutics has a 52 week low of $1.30 and a 52 week high of $4.08. The firm has a 50 day moving average of $1.51 and a two-hundred day moving average of $2.33.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AKBA. Geode Capital Management LLC lifted its holdings in shares of Akebia Therapeutics by 20.7% in the 2nd quarter. Geode Capital Management LLC now owns 6,074,458 shares of the biopharmaceutical company’s stock worth $22,115,000 after purchasing an additional 1,043,718 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Akebia Therapeutics by 21.7% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,180,759 shares of the biopharmaceutical company’s stock worth $4,298,000 after buying an additional 210,925 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in Akebia Therapeutics in the second quarter valued at $59,000. Assenagon Asset Management S.A. bought a new stake in Akebia Therapeutics in the third quarter valued at $1,165,000. Finally, Acadian Asset Management LLC bought a new position in shares of Akebia Therapeutics during the second quarter worth about $4,913,000. Institutional investors own 33.92% of the company’s stock.

Insider Activity at Akebia Therapeutics

In related news, CAO Richard C. Malabre sold 49,524 shares of Akebia Therapeutics stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.39, for a total value of $68,838.36. Following the completion of the transaction, the chief accounting officer directly owned 299,390 shares in the company, valued at approximately $416,152.10. This trade represents a 14.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.00% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.